Vibeke Vergote

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · The Lancet · 2024 · 136 citations · Full text

Medicine, Hematology, Oncology +10

Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial

Anna‐Katharina Zoellner, Michael Unterhalt, Stephan Stilgenbauer et al. · The Lancet Haematology · 2021 · 53 citations · Full text

Medicine, Hematology, Oncology +17

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Pier Luigi Zinzani, Vincent Delwail, Shankara Paneesha et al. · Blood · 2020 · 11 citations

Medicine, Oncology, Pharmacotherapy +9